Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement
Cristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J. Vargas-Brochero, Charat Thongprayoon, Jose A. Meade-Aguilar, Samuel D. Falde, Ulrich Specks, Fernando C. Fervenza, Ladan Zand · 2026
Read Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement by Cristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J. Vargas-Brochero, Charat Thongprayoon, Jose A. Meade-Aguilar, Samuel D. Falde, Ulrich Specks, Fernando C. Fervenza, Ladan Zand (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13586681.txt.
Description
IntroductionAvacopan has shown efficacy as a glucocorticoid-sparing therapy in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but its benefit in patients with severe renal involvement treated with rituximab remains uncertain.MethodsWe conducted a retrospective comparative cohort study at Mayo Clinic including patients with AAV and estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.
Catalog record
| CREATOR | Cristián Juanet, Isabel Hassi, Anila Cara, Cristina García Majado, Jose Arriola-Montenegro, Trisha Laxamana, Gian Marco Berti, Maria J. Vargas-Brochero, Charat Thongprayoon, Jose A. Meade-Aguilar, Samuel D. Falde, Ulrich Specks, Fernando C. Fervenza, Ladan Zand |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |